Homocysteine and Retinal Emboli: The Blue Mountains Eye Study

American Journal of Ophthalmology

Volumn 142, Issue 2, 2006, Pages 322-324

  Chua, Brian ^a   Kifley, Annette ^a   Wong, Tien Y ^b   Mitchell, Paul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE PHOTOGRAPHY; FEMALE; GENDER; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; RISK; VENOUS BLOOD;

AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; EMBOLISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; NEW SOUTH WALES; ODDS RATIO; PREVALENCE; RETINAL ARTERY OCCLUSION; RETINAL VEIN OCCLUSION;

EID: 33746521706     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.03.039     Document Type: Article

References (7)

1. Wong T.Y., and Klein R. Retinal arteriolar emboli. epidemiology and risk of stroke. Curr Opin Ophthalmol 13 (2002) 142-146
2. Mitchell P., Wang J.J., Li W., Leeder S.R., and Smith W. Prevalence of asymptomatic retinal emboli in an Australian urban community. Stroke 28 (1997) 63-66
3. Cahill M.T., Stinnett S.S., and Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 136 (2003) 1136-1150
4. Weger M., Stanger O., Deutschmann H., et al. The role of hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with retinal artery occlusion. Am J Ophthalmol 134 (2002) 57-61
5. Graham I.M., Daly L.E., Refsum H.M., et al., The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA 277 (1997) 1775-1781
6. Austin R.C., Lentz S.R., and Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 (2004) S56-S64
7. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575